Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Equity Average (2022 - 2025)

Historic Equity Average for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $233.9 million.

  • Taysha Gene Therapies' Equity Average rose 13662.05% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 13662.05%. This contributed to the annual value of $73.2 million for FY2024, which is 9300.27% up from last year.
  • Taysha Gene Therapies' Equity Average amounted to $233.9 million in Q3 2025, which was up 13662.05% from $151.9 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Equity Average high stood at $233.9 million for Q3 2025, and its period low was -$43.1 million during Q3 2023.
  • For the 4-year period, Taysha Gene Therapies' Equity Average averaged around $55.7 million, with its median value being $52.5 million (2022).
  • Its Equity Average has fluctuated over the past 5 years, first crashed by 29955.57% in 2023, then soared by 101996.57% in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Equity Average stood at $5.8 million in 2022, then soared by 121.62% to $12.9 million in 2023, then soared by 520.85% to $80.2 million in 2024, then surged by 191.74% to $233.9 million in 2025.
  • Its Equity Average stands at $233.9 million for Q3 2025, versus $151.9 million for Q2 2025 and $63.3 million for Q1 2025.